Murchinson Ltd. Buys 8,889 Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

Murchinson Ltd. raised its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 0.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,708,879 shares of the biotechnology company’s stock after acquiring an additional 8,889 shares during the period. Oramed Pharmaceuticals comprises approximately 1.1% of Murchinson Ltd.’s investment portfolio, making the stock its 15th largest holding. Murchinson Ltd. owned 4.24% of Oramed Pharmaceuticals worth $4,170,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ORMP. BML Capital Management LLC lifted its position in shares of Oramed Pharmaceuticals by 62.1% during the 3rd quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company’s stock valued at $5,334,000 after buying an additional 837,153 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Oramed Pharmaceuticals during the 3rd quarter valued at $272,000. Renaissance Technologies LLC increased its holdings in shares of Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 108,700 shares during the period. Virtu Financial LLC purchased a new stake in shares of Oramed Pharmaceuticals in the first quarter worth $68,000. Finally, XTX Topco Ltd purchased a new position in Oramed Pharmaceuticals during the second quarter worth about $40,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ORMP. StockNews.com downgraded Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday. HC Wainwright restated a “neutral” rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Price Performance

Shares of NASDAQ ORMP opened at $2.46 on Wednesday. The stock has a market capitalization of $99.16 million, a P/E ratio of 22.36 and a beta of 1.70. Oramed Pharmaceuticals Inc. has a one year low of $2.00 and a one year high of $3.67. The firm’s 50 day simple moving average is $2.36 and its two-hundred day simple moving average is $2.38.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.